Sign in

Research summary ·

Efficacy and safety of MEK inhibitors for NF1-associated symptomatic, inoperable plexiform neurofibromas: A systematic review and meta-analysis.

Written based on 1 research study on PubMed, searched on 3 Nov 2026.

What was studied

This review looked at MEK inhibitor drugs for symptomatic plexiform neurofibromas linked to NF1. These tumors cannot be removed by surgery. The team searched several databases. They pooled studies with 528 people. Children and adults were included. Several drugs were covered. The main outcome was how many tumors shrank by a set amount.

What they found

The pooled response rate was higher in children than in adults. The only randomized trial was KOMET. It found more responses with the drug than with placebo. Responses were partial but usually lasted. Pain and quality of life improved. Side effects were mostly low grade. Heart and eye problems were uncommon. In adults, KOMET drove most of the differences between studies.

What it means for patients

The authors say MEK drugs shrink symptomatic tumors that cannot be removed. This holds for children and adults. They say this is now backed by randomized evidence. They add that the gain is partial. It depends on staying on treatment.

Why it is not certain yet

Most of the groups were single-arm. So the pooled rates are not controlled effects. The pooled number averages several different drugs. The ideal length of treatment is not defined. Effects on malignant change are also not defined.

Source

Efficacy and safety of MEK inhibitors for NF1-associated symptomatic, inoperable plexiform neurofibromas: A systematic review and meta-analysis.

PubMed · PMID 42837360

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Childhood cancers publications
Efficacy and safety of MEK inhibitors for NF1-associated symptomatic, inoperable plexiform neurofibromas: A systematic review and meta-analysis. · Childhood cancers news explained – Frontlight Research